Featured Research

from universities, journals, and other organizations

Antidepressant proves effective in alleviating osteoarthritis pain

Date:
March 22, 2012
Source:
Wiley-Blackwell
Summary:
Antidepressants can play a key role in alleviating painful conditions like osteoarthritis and may result in fewer side effects than traditionally prescribed drug regimes, such as anti-inflammatories and opioids, according to new research.

Antidepressants can play a key role in alleviating painful conditions like osteoarthritis and may result in fewer side effects than traditionally prescribed drug regimes, such as anti-inflammatories and opioids, according to a perspective paper published online ahead of print publication by the International Journal of Clinical Practice.

Related Articles


American doctors Leslie Citrome and Amy Weiss-Citrome analysed the latest clinical evidence on duloxetine, a well-established antidepressant that received US Food and Drug Administration (FDA) approval in 2010 for use with chronic musculoskeletal pain, including osteoarthritis.

"It is not uncommon to treat osteoarthritis with a combination of drugs that work in different ways" explains Dr Leslie Citrome, Clinical Professor of Psychiatry and Behavioural Sciences at New York Medical College, Valhalla, New York, USA. "Our review supports this approach and confirms that antidepressants are not just for depression and can play a key role in relieving this painful condition."

The authors looked at studies exploring the effects of duloxetine being used on its own or in combination with non-steroidal anti-inflammatory drugs (NSAIDs). These included the two randomised double-blind, placebo controlled clinical trials that formed the basis of FDA approval for duloxetine for the treatment of chronic pain associated with osteoarthritis.

Study results were analysed using number needed to treat (NNT) and number needed to harm (NNH). These quantify how many patients need to be treated with one intervention versus another before encountering one additional patient who experiences a desired outcome (NNT) or undesired disadvantage, such as a side-effect (NNH). A smaller number indicates greater advantages for NNT and greater disadvantages for NNH.

"Applying these simple methods to often complex research gives us a real indication of whether a drug will benefit or harm our patients, which is what we as clinicians are most interested in" explains Dr Citrome.

When duloxetine was compared with a placebo tablet containing no active ingredients, using data from the two FDA approval studies, the NNT was six. This means that six patients would need to be treated with duloxetine instead of receiving the placebo before encountering one additional patient experiencing an improvement in pain using a composite measure that brings together a number of indicators of efficacy. Such a low NNT makes a compelling case for this treatment approach.

The authors say that this finding, over 13 weeks, compared favourably with other studies of NSAIDs -- the NNT was five for etodolac after four weeks and four for tenoxicam after eight weeks.

When the side effects of the various drugs were taken into account, this showed that when duloxetine was used on its own for 13 weeks it provided a number of advantages over NSAIDs, which can lead to gastrointestinal bleeding, and opiates such as morphine, which can cause constipation.

The most common side effects of duloxetine -- nausea, fatigue and constipation -- were small when compared to the placebo, resulting in NNHs of 16, 17 and 19 respectively. This means, for example, that 16 patients would need to be treated with duloxetine instead of receiving the placebo before encountering one additional patient experiencing nausea.

The studies used to gain FDA approval also showed that pain reduction using duloxetine on its own was not dependent on an improvement in depressive symptoms.

"Although the use of duloxetine as a monotherapy for pain has been approved by the regulatory agencies, it is quite common for patients to receive a combination of drugs and NSAIDs are the most frequently prescribed drugs for the pain associated with osteoarthritis" says co-author Dr Amy Weiss-Citrome, a specialist in Physical Medicine and Rehabilitation.

For that reason the authors also examined the findings of a recent study that showed the potential synergy of duloxetine and NSAIDs.

The study, a ten-week double-blind trial of 524 patients with osteoarthritis of the knee, found that those who took a combination of duloxetine and NSAIDs reported greater pain reductions than the control group who took a NSAID with a placebo.

The NNT for the outcome of substantial improvement in pain with combination treatment versus NSAIDs alone was six, underlining the benefits of this approach.

"We believe that our analysis of these studies demonstrate that clinicians managing patients suffering from osteoarthritis should also consider prescribing adjunctive antidepressants that can effectively impact on central pain pathways" concludes Dr Leslie Citrome.


Story Source:

The above story is based on materials provided by Wiley-Blackwell. Note: Materials may be edited for content and length.


Journal Reference:

  1. Citrome L and Weiss-Citrome A. Antidepressants and the relief of osteoarthritic pain – Findings from a study examining adjunctive duloxetine. International Journal of Clinical Practice, 2012 DOI: 10.1111/j.1742-1241.2012.02899.x

Cite This Page:

Wiley-Blackwell. "Antidepressant proves effective in alleviating osteoarthritis pain." ScienceDaily. ScienceDaily, 22 March 2012. <www.sciencedaily.com/releases/2012/03/120322095856.htm>.
Wiley-Blackwell. (2012, March 22). Antidepressant proves effective in alleviating osteoarthritis pain. ScienceDaily. Retrieved October 31, 2014 from www.sciencedaily.com/releases/2012/03/120322095856.htm
Wiley-Blackwell. "Antidepressant proves effective in alleviating osteoarthritis pain." ScienceDaily. www.sciencedaily.com/releases/2012/03/120322095856.htm (accessed October 31, 2014).

Share This



More Health & Medicine News

Friday, October 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Melafind: Spotting Melanoma Without a Biopsy

Melafind: Spotting Melanoma Without a Biopsy

Ivanhoe (Oct. 31, 2014) The MelaFind device is a pain-free way to check suspicious moles for melanoma, without the need for a biopsy. Video provided by Ivanhoe
Powered by NewsLook.com
Battling Multiple Myeloma

Battling Multiple Myeloma

Ivanhoe (Oct. 31, 2014) The answer isn’t always found in new drugs – repurposing an ‘old’ drug that could mean better multiple myeloma treatment, and hope. Video provided by Ivanhoe
Powered by NewsLook.com
Chronic Inflammation and Prostate Cancer

Chronic Inflammation and Prostate Cancer

Ivanhoe (Oct. 31, 2014) New information that is linking chronic inflammation in the prostate and prostate cancer, which may help doctors and patients prevent cancer in the future. Video provided by Ivanhoe
Powered by NewsLook.com
Sickle Cell: Stopping Kids’ Silent Strokes

Sickle Cell: Stopping Kids’ Silent Strokes

Ivanhoe (Oct. 31, 2014) Blood transfusions are proving crucial to young sickle cell patients by helping prevent strokes, even when there is no outward sign of brain injury. Video provided by Ivanhoe
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins